Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIGHT Phase 1: Bemarituzumab + mFOLFOX6 in Advanced GI Cancer
NCT03343301Phase 1Completed
- Sponsor
- Five Prime Therapeutics, Inc.
- Start
- Nov 2017
- Primary completion
- Jan 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of bemarituzumab in gastrointestinal cancer, gastric cancer (GC) and gastroesophageal junction cancer (2 arms), sponsored by Five Prime Therapeutics, Inc. Primary endpoints: Number of Participants With Treatment-related Adverse Events >= Grade 2 and Number of Participants With Dose Limiting Toxicities at 28 days. Started Nov 2017; status: completed.
02
Drugs
bemarituzumab
03
Conditions
gastrointestinal cancergastric cancer (GC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT03343301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03343301.